Innovative Therapeutics Rectify Pharma is developing a novel class of oral small molecules called Positive Functional Modulators (PFMs), targeting membrane protein restoration and enhancement. This innovative platform offers opportunities to collaborate or supply specialized chemistry, formulation, or delivery technologies for advanced pharmaceutical development.

Strategic Funding and Growth With a significant $100 million funding round led by prominent investors and a small team of 11-50 employees, Rectify is positioned for rapid growth and expansion into diverse disease areas like liver, cardio-renal-metabolic, and neurodegenerative conditions, creating potential sales avenues for biotech services and partnerships.

Recent Scientific Recognition The company's recent presentation at the EASL 2025 Congress signals active engagement in hepatobiliary research, presenting opportunities to connect with its scientific leadership for partnership, technology licensing, or collaborative research projects.

Leadership and Talent Key personnel hires, including experienced biotech leaders and scientific advisors, suggest a progressive company culture open to innovative partnerships and strategic collaborations with suppliers of research tools, clinical trial support, and specialized reagents.

Market Expansion Potential Operating in the competitive biotech space alongside industry giants and focusing on disease-modifying therapies for complex conditions, Rectify’s platform offers opportunities to introduce complementary technologies such as assay development, biomarker discovery, and drug delivery systems to accelerate clinical development and commercialization.